Newamsterdam pharma reports inducement grants under nasdaq listing rule 5635(c)(4)

Naarden, the netherlands and miami, jan. 09, 2025 (globe newswire) -- newamsterdam pharma company n.v. (nasdaq: nams; “newamsterdam” or the “company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“cvd”) with elevated low-density lipoprotein cholesterol (“ldl-c”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the compensation committee of newamsterdam's board of directors approved the grant of inducement share options covering an aggregate of 58,000 of newamsterdam's ordinary shares to two non-executive new hires and a grant of inducement share options covering 170,800 of newamsterdam's ordinary shares to maryellen mcquade, the company's new chief people officer. the share options were granted as an inducement material to the employees' acceptance of employment with newamsterdam pursuant to the newamsterdam pharma company n.v. 2024 inducement plan (the “2024 inducement plan”) and in accordance with nasdaq listing rule 5635(c)(4).
NAMS Ratings Summary
NAMS Quant Ranking